摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

phenylphosphonous acid | 121-70-0

中文名称
——
中文别名
——
英文名称
phenylphosphonous acid
英文别名
benzenephosphonous acid;Phenylphosphonige Saeure;Phenylphosphorige Saeure;Phenyl-phosphonigsaeure;Phenylphosphorigsaeure;Phenyl-phosphinsaeure;Hydroxyphenylphosphine oxide
phenylphosphonous acid化学式
CAS
121-70-0
化学式
C6H7O2P
mdl
——
分子量
142.094
InChiKey
CGNKSELPNJJTSM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    83-85 °C(lit.)
  • 沸点:
    302.3±25.0 °C(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.5
  • 重原子数:
    9
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    40.5
  • 氢给体数:
    2
  • 氢受体数:
    2

安全信息

  • 危险品标志:
    C
  • 危险类别码:
    R22,R34
  • 危险品运输编号:
    UN 3261 8/PG 3
  • WGK Germany:
    3
  • RTECS号:
    SZ5462500
  • 海关编码:
    2931900090
  • 安全说明:
    S26,S36/37/39,S45

SDS

SDS:3b27342e31a8fa500d684698c4648d14
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    phenylphosphonous acid 在 dinitrogen tetraoxide 作用下, 以 为溶剂, 生成 Phenylphosphonsaeure-monobutylester
    参考文献:
    名称:
    Petrov,K.A. et al., Journal of general chemistry of the USSR, 1962, vol. 32, p. 1250 - 1252
    摘要:
    DOI:
  • 作为产物:
    描述:
    苯基二氯化磷盐酸 作用下, 以 为溶剂, 生成 phenylphosphonous acid
    参考文献:
    名称:
    Process for the preparation of phosphonous acids
    摘要:
    磷酸类可通过将二氯膦与水在60℃到100℃的温度下水解获得,最好在80℃到95℃之间。
    公开号:
    US04485052A1
点击查看最新优质反应信息

文献信息

  • Probing the Mechanism of Allylic Substitution of Morita–Baylis–Hillman Acetates (MBHAs) by using the Silyl Phosphonite Paradigm: Scope and Applications of a Versatile Transformation
    作者:Maria Kalyva、Alexandros L. Zografos、Era Kapourani、Evaggelos Giambazolias、Laurent Devel、Athanasios Papakyriakou、Vincent Dive、Yannis G. Lazarou、Dimitris Georgiadis
    DOI:10.1002/chem.201405626
    日期:2015.2.16
    using 31P NMR spectroscopy revealed unexpected reactivity differences between ester and nitrile derivatives. These kinetic profiles and DFT calculations support a mechanistic scenario in which observed differences can be explained from the “lateness” of transition states. In addition, we provide experimental evidence suggesting that enolates due to initial P‐Michael addition are not formed. Based on
    AP 甲硅烷基膦酸酯和森田-的Baylis-希尔曼乙酸盐(MBHAs)之间C键形成反应探索作为向医药相关β-carboxyphosphinic结构基序的通用的替代方案。使用31记录的不同取代的MBHA转化为次膦酸9或14的转化率P NMR光谱显示酯和腈衍生物之间的反应性差异出乎意料。这些动力学曲线和DFT计算支持了一种机械方案,其中可以从过渡态的“迟缓”解释观察到的差异。此外,我们提供的实验证据表明,由于最初的P-Michael加成而形成的烯醇不形成。基于拟议的机械情景结合DFT计算,对E / Z的解释提出了酯和腈之间的立体选择性差异。提出了由这种转变产生的合成机会,该机会涉及几种合成的反复变化的膦基结构单元的制备,而这些结构单元通过经典的P-Michael合成路线的访问并不简单。
  • [EN] COMPOUNDS COMPRISING PHOSPHORUS-CONTAINING METAL COMPLEXES<br/>[FR] COMPOSES COMPRENANT DES COMPLEXES METALLIQUES CONTENANT DU PHOSPHORE
    申请人:DU PONT
    公开号:WO2004016710A1
    公开(公告)日:2004-02-26
    Compounds comprising phosphorus-containing metal complexes can be used in electroluminescent devices and have an emission maximum closer to the blue region of the visible light spectrum. The complexes can be used within an organic active layer in electronic devices, such as displays, detectors, voltaic cells, solid-state lighting, illumination devices or the like. The complexes may also be used as catalysts or as indicators in other applications. The new compounds can be used without the need of a host material. In non-limiting embodiments, Pt or Ir may be used for the metal atom within the complex, one ligand may include a phosphorus-containing bidentate ligand, and another ligand may include a monoanionic bidentate ligand. The phosphorus-containing bidentate ligand may include a benzyl group, a phenoxy group, a phenylamino group, or the like.
    含磷金属配合物的化合物可用于电致发光器件,并且其发射峰值更接近可见光谱的蓝色区域。这些配合物可用于电子器件中的有机活性层,如显示器、探测器、伏打电池、固态照明、照明设备等。这些配合物也可用作催化剂或其他应用中的指示剂。这些新化合物可在无需宿主材料的情况下使用。在非限制性实施例中,金属原子可以使用Pt或Ir,一个配体可以包括含磷的双齿配体,另一个配体可以包括单阴离子双齿配体。含磷的双齿配体可以包括苄基、苯氧基、苯胺基等。
  • Preparation of acylaminomethanephosphonic acids and
    申请人:Hoechst Aktiengesellschaft
    公开号:US05432291A1
    公开(公告)日:1995-07-11
    Acylaminomethanephosphinic acids, and a process for the preparation of acylaminomethanephosphonic acids and acylaminomethylphosphinic acids Acylaminomethanephosphonic acid and acylaminomethylphosphinic acids of the formula I, R.sup.2 --CO--NH--CH.sub.2 --P(O)(OH)R.sup.1 (I) in which R.sup.1 is hydroxyl, C.sub.1 -C.sub.4 -alkyl or phenyl and R.sup.2 is H, C.sub.1 -C.sub.6 -alkyl, benzyl or phenyl, unsubstituted or substituted by one or more radicals from the group comprising C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy and halogen, are valuable intermediates for the preparation of biologically active compounds. They can be prepared by reacting a compound of the formula II R.sup.2 --CO--NH--CH.sub.2 --OH (II) with compounds of the formula III, H--P(O)(OH)R.sup.1 (III) in the presence of an at least equimolar amount of acetic anhydride, based on the compound of the formula II. The compounds of the formula (I) where R.sup.1 is other than hydroxyl, are novel.
    酰胺甲磷酸和酰胺甲基膦酸的制备方法酰胺甲磷酸和式I的酰胺甲基膦酸,R.sup.2--CO--NH--CH.sub.2--P(O)(OH)R.sup.1(I),其中R.sup.1为羟基、C.sub.1-C.sub.4-烷基或苯基,R.sup.2为H、C.sub.1-C.sub.6-烷基、苄基或苯基,未经取代或经由C.sub.1-C.sub.4-烷基、C.sub.1-C.sub.4-烷氧基和卤素等基团的取代,对于生物活性化合物的制备是有价值的中间体。它们可以通过将式II的化合物R.sup.2--CO--NH--CH.sub.2--OH(II)与式III的化合物H--P(O)(OH)R.sup.1(III)在存在至少等摩尔量的乙酸酐的情况下反应制备,基于式II的化合物。其中R.sup.1不为羟基的式(I)化合物是新颖的。
  • Method for making phosphinic acid intermediates
    申请人:E. R. Squibb & Sons, Inc.
    公开号:US04594199A1
    公开(公告)日:1986-06-10
    A method is provided for preparing phosphinic acid prodrug intermediates which are useful in preparing phosphinic acid angiotensin-converting enzyme inhibitors which method includes the step of coupling a phosphonous acid or its ester of the structure ##STR1## wherein R is H or lower alkyl and R.sup.1 is lower alkyl, aryl, arylalkyl, cycloalkyl or cycloalkylalkyl, with a conjugated compound of the structure ##STR2## wherein R.sup.2, R.sup.3 and R.sup.4 may be the same or different and each is independently H, lower alkyl or aryl, and Z is --CO.sub.2 R.sup.5 (wherein R.sup.5 is H or lower alkyl), ##STR3## (wherein R.sup.6 is H, lower alkyl aryl or arylalkyl), ##STR4## (wherein R.sup.7 and R.sup.8 are the same or different and are selected from the group consisting of H, lower alkyl, aryl, aryl-lower alkyl, cycloalkyl or cycloalkylalkyl and at least one of R.sup.7 and R.sup.8 is other than H, or R.sup.7 and R.sup.8 can be taken together with N to form a 5-, 6- or 7-membered heterocyclic ring ##STR5## which may or may not include a COOR.sup.5 substituent, which 5- or 6-membered N-containing ring may or may not be fused to an aryl ring), in the presence of a silylating agent, to form the phosphonic acid intermediate of the structure ##STR6## wherein R, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 and Z are as defined above.
    提供了一种制备磷酸前药中间体的方法,该方法用于制备磷酸盐肽酶抑制剂,其中该方法包括以下步骤:将具有结构##STR1##的磷酸盐或其酯(其中R为H或低碳烷基,R.sup.1为低碳烷基、芳基、芳基烷基、环烷基或环烷基烷基)与具有结构##STR2##的共轭化合物偶联,其中R.sup.2、R.sup.3和R.sup.4可以相同也可以不同,且每个独立地为H、低碳烷基或芳基,Z为--CO.sub.2 R.sup.5(其中R.sup.5为H或低碳烷基),##STR3##(其中R.sup.6为H、低碳烷基、芳基或芳基烷基),##STR4##(其中R.sup.7和R.sup.8可以相同也可以不同,选自H、低碳烷基、芳基、芳基-低碳烷基、环烷基或环烷基烷基群,且R.sup.7和R.sup.8中至少有一个不是H,或R.sup.7和R.sup.8可以与N一起形成5、6或7-成员杂环环##STR5##,该环可能包括或不包括COOR.sup.5取代基,该含N的5-或6-成员环可能与芳基环融合或不融合),在硅基化剂存在下,形成结构为##STR6##的磷酸中间体,其中R、R.sup.1、R.sup.2、R.sup.3和R.sup.4以及Z如上定义。
  • Synthesis, structure and reactivity of cuboidal-type cluster aqua complexes with W<sub>3</sub>PdS<sub>4</sub><sup>4+</sup>core
    作者:Rita Hernández Molina、Irina Kalinina、Maxim Sokolov、Maria Clausen、Javier González Platas、Cristian Vicent、Rosa Llusar
    DOI:10.1039/b613790c
    日期:——
    PdCl(2) with [W3S4(H2O)9]4+ in the presence of hypophosphorous acid in 2 M HCl gives cuboidal cluster [W3(PdCl)S4(H2O)9]3+ (1) which undergoes condensation and crystallises from Hpts solutions as edge-linked double cubane cluster [W3PdS4(H2O)9}2](pts)(8).19H2O (pts = p-toluenesulfonate) (1'). The substitution of Cl- in (1) by different ligands was explored. The Pd atom in the cluster shows an exceptionally
    PdCl(2)与[W3S4(H2O)9] 4+在次磷酸存在下于2 M HCl中反应,得到长方体簇[W3(PdCl)S4(H2O)9] 3+(1),其经过缩合和从Hpts溶液中结晶为边缘连接的双古巴铜团簇[W3PdS4(H2O)9} 2](pts)(8).19H2O(pts =对甲苯磺酸盐)(1')。探索了用不同的配体取代(1)中的Cl-。簇中的Pd原子在氢磷酰基H2P(O)(OH),HP(O)(OH)2,HPPh(O)(OH)和HPPh2(O)分子异构化中显示出异常高的反应性羟基互变异构体HP(OH)2,P(OH)3,PhP(OH)2和Ph2P(OH)通过在Pd上的配位稳定化。通过UV-Vis分光光度法和31P NMR追踪反应。获得了[M3(PdCl)S4(H2O)9] 3+(M = Mo,W)与HP(OH)2和As(OH)3的1:1配位的形成常数。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐